Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification-Reference-Cited by-同舟云学术

Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification

Published:2014-10-01 Issue:3 Volume:17 Page:238-246
ISSN:1699-048X
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

García Fernández A.,Chabrera C.,García Font M.,Fraile M.,Lain J. M.,Gónzalez S.,Barco I.,González C.,Torres J.,Piqueras M.,Cirera L.,Veloso E.,Pessarrodona A.,Giménez N.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12094-014-1220-8.pdf

Reference34 articles.

1. Reed SD, Dinan MA, Schulman KA, Lyman GH. Cost-effectiveness of the 21-Gene Recurrence Score Assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med. 2013;15:203–11.

2. Hannouf MB, Xie B, Brackstone M, Zaric GS. Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer. BMC Cancer. 2012;12:447.

3. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization. Value Health. 2010;13:381–7.

4. Hall PS, McCabe C, Stein RC, Cameron D. Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst. 2012;104:56–66.

5. Eiermann W, Rezai M, Kummel S, Kühn T, Warm M, Friedrichs K, et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol. 2013;24:618–24.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer;Medicine;2023-08-25

2. Predicting of Ki-67 Expression Level Using Diffusion-Weighted and Synthetic Magnetic Resonance Imaging in Invasive Ductal Breast Cancer;The Breast Journal;2023-04-05

3. The prognostic impact of body mass index on female breast cancer patients in underdeveloped regions of northern China differs by menopause status and tumor molecular subtype;Open Life Sciences;2023-01-01

4. Transcriptomics and Proteomics Characterizing the Anticancer Mechanisms of Natural Rebeccamycin Analog Loonamycin in Breast Cancer Cells;Molecules;2022-10-17

5. Clinico-pathologic factors associated with the occurrence of early and late metastatic spread in a cohort of breast cancer patients;Breast Disease;2022-08-31